Effects of dihydromyricetin on wear-particle-induced osteolysis in murine calvarial model

doi:10.12092/j.issn.1009-2501.2018.07.001

Abstract

Abstract:

AIM: To investigate the effects of dihydromyricetin (DMY) on wear-particle-induced osteolysis in murine calvarial model. METHODS: Thirty male C57BL/J6 mice were randomly divided into the sham group, the control group, and the DMY group (10 in each group). Except for the mice from the sham group, mice from the control group and DMY group received 30 mg Ti particles into calvaria to induce osteolysis in murine calvarial model. Mice from the DMY group were gavage-fed daily with DMY of 500 mg/kg, while mice from the sham group and control group were gavage-fed daily with saline. Calvaria and vein blood samples from each group were harvested for further micro-CT and pathological analysis at the 14th after the surgery. RESULTS:Micro-CT showed that the severity of osteolysis was significantly reduced in DMY group. And the BMD of the samples in DMY group was significantly higher than that of the control group（P<0.05）. By the HE and TRAP staining analysis, less osteoclasts were found in the samples in DMY group. In addition, the application of DMY also decreased the serum TNF-α, IL-1β, and RANKL level yet improved OPG level as compared with the positive control group（P<0.05）. DMY could significantly inhibit the differentiation of RANKL-induced osteoclast by in vitro cell culture experiments.CONCLUSION: DMY can inhibit the wear-particle-induced osteolysis in murine calvarial model.

Key words: mouse, dihydromyricetin, Ti particles, osteoclast, osteolysis

CLC Number:

R965.2

HUANG Donghui, ZHENG Hangsheng. Effects of dihydromyricetin on wear-particle-induced osteolysis in murine calvarial model[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 721-727.

References

[1］Apostu D, Lucaciu O, Berce C, et al. Current methods of preventing aseptic loosening and improving osseointegration of titanium implants in cementless total hip arthroplasty: a review[J］. J Int Med Res, 2017.
[2］Eastwood SE, John A, Jones SA, et al. Osteoclastogenesis-related cytokines and peri-prosthetic osteolysis in revision metal-on-metal total hip replacements[J］. Hip Int, 2015, 25(4): 355-360.
[3］Müller M, Wassilew G, Perka C. Diagnosis and therapy of particle disease in total hip arthroplasty[J］. Z Orthop Unfall, 2015, 153(2): 213-229.
[4］Samujh C, Bhimani S, Smith L, et al. Wear analysis of second-generation highly cross-linked polyethylene in primary total hip arthroplasty[J］. Orthopedics, 2016, 39(6): 1.
[5］Ponzio DY, Austin MS. Metaphyseal bone loss in revision knee arthroplasty [J］. Curr Rev Musculoskelet Med, 2015, 8(4): 361-367.
[6］Qian Y, Zhang XL, Jiang Y, et al. Alendronate stimulates osteoprotegerin expression in fibroblasts from periprosthetic membrane[J］. Hip Int, 2015, 25(6): 581-584.
[7］Chen Y, Lv L, Pi H, et al. Dihydromyricetin protects against liver ischemia/reperfusion induced apoptosisviaactivation of FOXO3a-mediated autophagy[J］. Oncotarget, 2016, 7(47): 76508-76522.
[8］Li X, Liu J, Lin J, et al. Protective effects of dihydromyricetin against OH-induced mesenchymal stem cells damage and mechanistic chemistry[J］. Molecules, 2016, 21(5): 604.
[9］Lei L, Jing W, Lang H, et al. Dihydromyricetin delays the onset of hyperglycemia and ameliorates insulin resistance without excessive weight gain in Zucker diabetic fatty rats[J］. Mol Cell Endocrinol, 2017, 439: 105-115.
[10］Huang H, Hu M, Zhao R, et al. Dihydromyricetin suppresses the proliferation of hepatocellular carcinoma cells by inducing G2/M arrest through the Chk1/Chk2/Cdc25C pathway[J］. Oncol Rep, 2013, 30(5): 2467-2475.
[11］Huang X, Lian T, Guan X, et al. Dihydromyricetin reduces TGF-β via P53 activation- dependent mechanism in hepatocellular carcinoma HepG2 cells[J］. Protein Pept Lett, 2017, 24(5): 419-424.
[12］Tang N, Ma J, Ke SW, et al. Dihydromyricetin suppresses TNF-α-induced NF-κB activation and target gene expression[J］. Mol Cell Biochem, 2016, 422(1/2): 11-20.
[13］Wang R, Pi J, Su X, et al. Dihydromyricetin suppresses inflammatory responses in vitro and in vivo through inhibition of IKKβ activity in macrophages[J］. Scanning, 2016, 38(2): 119-124.
[14］Zhang W, Wang S, Yin H, et al. Dihydromyricetin enhances the osteogenic differentiation of human bone marrow mesenchymal stem cells in vitro partially via the activation of Wnt/β-catenin signaling pathway[J］. Fundam Clin Pharmacol, 2016, 30(6): 596-606.
[15］Bostikova Z, Moserova M, Pavek P, et al. Role of dihydromyricetin in cytochrome P450-mediated metabolism and carcinogen activation[J］. Neuro Endocrinol Lett, 2015, 36(Suppl 1): 46-52.
[16］Hodek P, Fousova P, Brabencova E, et al. Effect of dihydromyricetin on benzo[a］ pyrene activation in rats[J］. Neuro Endocrinol Lett, 2014, 35(Suppl 2): 158-168.
[17］Liang J, Shen Y, Shao XM, et al. Dihydromyricetin prevents fetal alcohol exposure-induced behavioral and physiological deficits: the roles of GABAA receptors in adolescence[J］. Neurochem Res, 2014, 39(6): 1147-1161.
[18］Wu B, Jie L, Jian L, et al. Dihydromyricetin protects against diabetic cardiomyopathy in streptozotocin-induced diabetic mice[J］. Biomed Res Int, 2017, 2017(1): 1-13. [19］Eger M, Sterer N, Liron T, et al. Scaling of titanium implants entrains inflammation-induced osteolysis[J］. Sci Rep, 2017, 1(7): 39612.
[20］Ping Z, Hu X, Wang L, et al. Melatonin attenuates titanium particle-induced osteolysis via activation of Wnt/β-catenin signaling pathway [J］. Acta Biomater, 2017, 10(51): 513-525.
[21］Zeng X, Zhang Y, Wang S, et al. Artesunate suppresses RANKL-induced osteoclastogenesis through inhibition of PLCγ1-Ca-NFATc1 signaling pathway and prevents ovariectomy-induced bone loss[J］. Biochem Pharmacol, 2017, 124: 57-68.
[22］Zhu L, Kang H, Guo CA, et al. Rifampin suppresses osteoclastogenesis and titanium particle-induced osteolysis via modulating RANKL signaling pathways[J］. Biochem Biophys Res Commun, 2017, 484(1): 64-70.
[23］Takada R, Jinno T, Koga D, et al. Comparison of wear rate and osteolysis between second-generation annealed and first-generation remelted highly cross-linked polyethylene in total hip arthroplasty. A case control study at a minimum of five years[J］. Orthop Traumatol Surg Res, 2017, 103(4): 537-541.
[24］Thienpont E. Titanium niobium nitride knee implants are not inferior to chrome cobalt components for primary total knee arthroplasty[J］. Arch Orthop Trauma Surg, 2015, 135(12): 1749-1754.
[25］Dalling JG, Math K, Scuderi GR. Evaluating the progression of osteolysis after total knee arthroplasty[J］. J Am Acad Orthop Surg, 2015, 23(3): 173-180.
[26］Ji FJ, Tian XF, Liu XW, et al. Dihydromyricetin induces cell apoptosis via a p53-related pathway in AGS human gastric cancer cells[J］. Genet Mol Res, 2015, 14(4): 15564-15571.
[27］Liu S, Ai Q, Kai F, et al. The cardioprotective effect of dihydromyricetin prevents ischemia-reperfusion-induced apoptosis in vivo and in vitro via the PI3K/Akt and HIF-1α signaling pathways[J］. Apoptosis, 2016, 21(12): 1366-1385.
[28］Wang Z, Sun X, Feng Y, et al. Dihydromyricetin reverses MRP2-mediated MDR and enhances anticancer activity induced by oxaliplatin in colorectal cancer cells[J］. Anti-cancer Drugs, 2017, 28(3): 281-288.
[29］侯小龙, 王文清, 施春阳, 等. 二氢杨梅素药理作用研究进展[J］. 中草药, 2015, 46(4): 603-609.
[30］Liu L, Yin X, Wang X, et al. Determination of dihydromyricetin in rat plasma by LC-MS/MS and its application to a pharmacokinetic study[J］. Pharm Biol, 2017, 55(1): 657-662.
[31］Liu P, Zou D, Chen K, et al. Dihydromyricetin improves hypobaric hypoxia-induced memory impairment via modulation of SIRT3 signaling[J］. Mol Neurobiol, 2016, 53(10): 7200-7212.

[1]	YE Xiaodi, MIAO Yunping, CHEN Aiying, CHENG Min, TIAN Xuejun, ZHENG Gaoli . Optimization and verification of orthotopic non-muscle invasive bladder cancer model in nude mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 473-480.
[2]	LIU Yunfan, DU Yuemei, LIU Xiaoyi, GAO Liping. Effects of lycium barbarum polysaccharides on cis-dichlorodiamineplatinum (II)-induced apoptosis in mouse testis sertoli cells TM4#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 624-630.
[3]	JIANG Haoming，CHEN Xiang, LI Zhen, GU Chengping. Clinical efficacy of monosialotetrahexose ganglioside combined with mouse nerve growth factor in the treatment of neonatal hypoxic ischemic encephalopathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 301-306.
[4]	LI Gang, KUANG Chao, MENG Zan, ZHOU Liang, MA Jing, LUO Yan-min, LI Zao, LIU Pin-yue, HE Jie, TANG Yong, LIU Yong-gang. Neuroprotective effect of fluoxetine on the APP/PS1 transgenic mouse model of Alzheimer's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 514-519.
[5]	YUAN Dai-xiu, SHU Li-xia, HUANG Rong. Antitumor effects of total flavonoids of Eucommia ulmoides in tumor-bearing mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1332-1336.
[6]	LIU Qian, WANG Qing, ZHANG Xue-mei. Comparison of two kinds of diabetic model mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(9): 999-1003.
[7]	HONG Juan, WANG Xin-hong. Pathogenesis and treatment of the bone disease of multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(6): 705-709.
[8]	DING Jie-wei¹, WANG Jian-ping². Effects of atorvastatin on ApoA-I and SR-B1 in ApoE-deficient mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(11): 1233-1237.
[9]	LIU Qian, LI Xia-hui, ZHANG Xue-mei. Mouse models of type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(10): 1196-1200.
[10]	CHEN Zai-feng, XU Xin-long, WEI Xiao-jie, FU Xiao-jun, PAN Hong-song, XIE Qin-song. Differentiation of rat bone marrow stromal cells into neurol cells induced by mouse nervous growth factor [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 137-140.
[11]	ZHEN Dong-Hu, LIU Li-Juan, TANG Xu-Lei, CHEN Jian-Guo. Effects of metformin on bone metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(11): 1314-1320.
[12]	GAO Lin-na, HE Xiao-li, TANG Qian-qi, HE Guo-rong, BI Ming-gang. Effects of icariin on monoamine and amino acid neurotransmitters in senescence accelerated mouse prone/10 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(10): 1081-1086.
[13]	XU Xiao-yue, ZHANG Guang-wei, LI Zhan, ZHANG Li-li. Experimental study of antibacterial and antiviral activity about Tanreqing oral liquid [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(3): 274-278.
[14]	WU Yu-qing, ZHOU Cheng-hua, ZHANG Yong. Verapamil enhanced the analgesic effect of ketamine in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(11): 1201-1204.
[15]	FANG Hui-long, WANG Jun-jie, CHEN Mei-zi, JIA Lei, LI Chun-wei. Experimental study on therapeutic effects of dihydromyricetin on hepatic fibrosis in murine schistosomiasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(4): 381-384.